CliffBio
biologic

Imuldosa

ustekinumab-srlf

Loss of exclusivity—loss of exclusivity
CompanyAccord Biopharma →See this company's full patent-cliff portfolio

Drug detail

Brand nameImuldosa
Active ingredientustekinumab-srlf
Strength45MG/0.5ML
Dosage formInjection
RouteSubcutaneous
ModalityBiologic
FDA approvalOctober 2024
Marketing statusRx

More from Accord Biopharma

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

Imuldosa patent cliff — loss of exclusivity — | CliffBio